CONTENTS:
- Competing global statistics on prevalence of injecting drug use: why does it matter and what can be done? [Editorial]. Hickman M., Larney S., Peacock A., Jones H., Grebely J., Degenhardt L., p. 1768-1774.
- Gateway effects and electronic cigarettes [Addiction debate]. Etter J.F., p. 1776-1783.
- How can we protect youth from putative vaping gateway effects without denying smokers a less harmful option? Gartner C., p. 1784-1785.
- Multiple gateways. MacCoun R.J., p. 1785-1786.
- Electronic cigarettes: harm reduction tool or new substance use behavior? Mayet A., Lavagna C., p. 1786-1788.
- Comprehensive causal models and harm minimization principles should guide regulations on vapourizers. Etter J.F., p. 1788-1789.
- Drawing attention to a neglected injecting-related harm: a systematic review of AA amyloidosis among people who inject drugs. Harris M., Brathwaite R., Scott J., Gilchrist G., Ciccarone D., Hope V., et al., p. 1790-1801.
- National Cancer Societies and their public statements on alcohol consumption and cancer risk. Amin G., Siegel M., Naimi T., p. 1802-1808.
- Commentary on Amin et al. (2018): Cancer societies must do better on alcohol. Pratt I.S., Kameron C.B., p. 1809-1810.
- Adverse adult consequences of different alcohol use patterns in adolescence: an integrative analysis of data to age 30 years from four Australasian cohorts. Silins E., Horwood L.J., Najman J.M., Patton G.C., Toumbourou J.W., Olsson C.A., et al., p. 1811-1825.
- Estimating mental health impacts of alcohol's harms from other drinkers: using propensity scoring methods with national cross-sectional data from the United States. Karriker-Jaffe K.J., Li L., Greenfield T.K., p. 1826-1839.
- Effectiveness, safety and feasibility of extended-release naltrexone for opioid dependence: a 9-month follow-up to a 3-month randomized trial. Solli K.K., Latif Z.E., Opheim A., Krajci P., Sharma-Haase K., Benth J.S., et al., p. 1840-1849.
- Evolution of clinical characteristics and outcomes of synthetic cannabinoid receptor agonist exposure in the United States: analysis of National Poison Data System data from 2010 to 2015. Cordeiro S.K., Daro R.C., Seung H., Klein-Schwartz W., Kim H.K., p. 1850-1861.
- Prevalence of youth gambling and potential influence of substance use and other risk factors throughout 33 European countries: first results from the 2015 ESPAD study. Molinaro S., Benedetti E., Scalese M., Bastiani L., Fortunato L., Cerrai S., et al., p. 1862-1873.
- 'Real-world' compensatory behaviour with low nicotine concentration e-liquid: subjective effects and nicotine, acrolein and formaldehyde exposure. Dawkins L., Cox S., Goniewicz M., McRobbie H., Kimber C., Doig M., et al., p. 1874-1882.
- Cigarette brand diversity and price changes during the implementation of plain packaging in the United Kingdom. Breton M.O., Britton J., Huang Y., Bogdanovica I., p. 1883-1894.
- Fetal assessment in buprenorphine-maintained women using fetal magnetoencephalography: a pilot study. Escalona-Vargas D., Coker J.L., Ray-Griffith S., Siegel E.R., Lowery C.L., Stowe Z.N., et al., p. 1895-1904.
- Global statistics on alcohol, tobacco and illicit drug use: 2017 status report. Peacock A., Leung J., Larney S., Colledge S., Hickman M., Rehm J., et al., p. 1905-1926.
- Denise Kandel's classic work on the gateway sequence of drug acquisition. Lynskey M.T., Agrawal A., p. 1927-1932.
- Imaging resilience and recovery in alcohol dependence. Charlet K., Rosenthal A., Lohoff F.W., Heinz A., Beck A., p. 1933-1950.
- The therapeutic potential of kratom. Grundmann O., Brown P.N., Henningfield J., Swogger M., Walsh Z., p. 1951-1953.
- New Zealand court dismisses Ministry of Health case against 'heat-not-burn' tobacco products, highlighting the need to future-proof tobacco control laws. Rychert M., p. 1953-1954.